AUSTIN, Texas--(BUSINESS WIRE)--Appian Labs, LLC, a biopharmaceutical company specializing in advanced therapeutic design, announced today its launch as a new company focused on providing comprehensive and strategic drug delivery and design solutions for pharmaceutical and other bioactives companies worldwide. The company provides solutions for a number of drug delivery problems, including poor bioavailability or solubility, dose timing, toxicity and many others. Appian Labs is funded and managed by venture firm Emergent Technologies, Inc. (ETI).
Appian’s laboratory is led by Chief Scientist Nicholas Peppas, Sc.D., a pioneer in the field of drug delivery and controlled release chemistry over the last three decades. Dr. Peppas has published more than 1,050 peer-reviewed articles and 33 books, covering drug delivery, hydrogels, and related controlled release. He has made life-changing contributions to drug delivery and biomaterials applications using his recognized expertise in biomedical engineering and polymer chemistry.
Aptly named for the great, innovative feat of human engineering, the Appian Way, the leading delivery route of the ancient world, Appian Labs’ industry-leading scientist laid the foundation of the science and mathematical formulas used broadly in the modern drug delivery industry today. Now, employing the latest innovations in drug design and delivery, Appian Labs’ technologies will be utilized to develop next-generation drug formulations for safer and improved healthcare.
Drug Delivery by Design
Brian Windsor, Ph.D., President of Appian Labs, said, “Building on the drug delivery leadership of our scientific team, we can design delivery solutions tailored to pharma companies’ drugs and that improve bioavailability, dosing, or timing of a drug. Our breadth of expertise and technologies enables us to match virtually any kinetic profile desired.” The company’s first marketing initiative to potential pharmaceutical partners is an invitation to ‘Draw your own profile’ and Appian Labs will design a custom drug delivery system to match.
Windsor added, “Having worked with pharmaceutical companies for several decades to solve drug delivery problems, our scientific team knows both the common needs and the far-reaching goals of drug manufacturers.”
Nicolas Peppas, Sc.D.
Dr. Nicolas Peppas has received numerous awards for his multidisciplinary research in drug delivery, biomedical engineering and polymer chemistry. Recognized internationally as a leading scientist, he is a member of both the National Academy of Engineering and the French Academy of Pharmacy. In addition to serving as Chief Scientist of Appian Labs, Peppas will remain as the Fletcher Stuckey Pratt Chair in Engineering in the Departments of Chemical and Biomedical Engineering and Professor in the College of Pharmacy at the University of Texas at Austin.
About Appian Labs
Appian Labs, LLC is a biopharmaceutical company specializing in advanced therapeutic design. The company is focused on providing drug delivery and design solutions for biotech, pharmaceutical and life science companies worldwide. Appian Labs provides solutions for a number of drug delivery problems, including poor bioavailability or solubility, dose timing, toxicity and many others. Founded on the pioneering work in drug delivery systems of Chief Scientist Dr. Nicholas Peppas, the company designs tailor-made solutions to current drug delivery problems as well as innovative new formulations for the next generation of pharmaceuticals. Appian Labs is funded and managed by life sciences venture firm, Emergent Technologies, Inc. (ETI). For more information, visit the company website www.appianlabs.com
About Emergent Technologies, Inc.
Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on what the firm describes as invention capital. In addition to the traditional venture capital approach of raising and investing funds, ETI drives the selection and expansion of each technology assets unique to their region. ETI is pioneering a unique business approach to investment in intellectual property, the key asset to most technology-based start-up companies. For more information, visit the company website www.etibio.com
Nsight Public Relations
Sandra Oak, 321-591-1508
Source: Emergent Technologies, Inc.